49th week of 2008 patent applcation highlights part 51 |
Patent application number | Title | Published |
20080300215 | Prodrugs Activated by Rna-Dependent Dna-Polymerases - Herein described are prodrugs activated by RNA-dependent DNA-polymerases, such as telomerase and retroviral reverse transcriptases, their use for the treatment of haematological tumours and of blood and blood derivatives from patients affected by retroviral infections, and their use for the preparation of pharmaceutical compositions, to be used for the treatment of solid tumours, of precancerous states and of diseases caused by infection with retroviruses. | 2008-12-04 |
20080300216 | Dutpase Inhibitors - Deoxyuridine derivatives of Formula (I′); where A is O, S or CH | 2008-12-04 |
20080300217 | Combination Therapy with Fumaric Acid Esters for the Treatment of Autoimmune and/or Inflammatory Disorders - The present invention relates to compositions, kits and methods for administration of a first component of fumaric acid ester(s), or a pharmaceutically acceptable salt thereof, and a second component which is a substance that reduces or eliminates flushing. | 2008-12-04 |
20080300218 | CROSSLINKABLE POLYSACCHARIDE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, CROSSLINKABLE POLYSACCHARIDE COMPOSITION, AND MEDICAL TREATMENT MATERIAL - A process for producing an uncrosslinked, crosslinkable polysaccharide derivative having an active ester group, said process including: dissolving an acid-containing polysaccharide having a carboxy group and/or a carboxyalkyl group which are originally possessed or which have been introduced, in its non-salt form, into an aprotic polar solvent at a temperature of 60° C. to 120° C., and reacting it with an N-hydroxylamine-based electrophilic group-introducing reagent at a temperature between 0° C. and 70° C. in the presence of a dehydrating-condensing agent selected from the group consisting of 1-ethyl-3-dimethylaminopropylcarbodiimide hydrochloride and 1-cyclohexyl-(2-morphonyl-4-ethyl)-carbodiimide-meso-p-toluenesulfonate, and thereby converting at least part of said carboxy group and/or carboxyalkyl group into active esters bearing an N-hydroxylamine-based electrophilic group. | 2008-12-04 |
20080300219 | NOVEL INTERSTITIAL THERAPY FOR IMMEDIATE SYMPTOM RELIEF AND CHRONIC THERAPY IN INTERSTITIAL CYSTITIS - The present invention relates to a disorder of the lower urinary tract, and in particular, reducing the symptoms (including treatment) of interstitial cystitis in vivo. In a preferred embodiment, the present invention relates to treatment formulations and methods for reducing interstitial cystitis in patients. | 2008-12-04 |
20080300220 | Linkable Lewis X Analogs - Disclosed herein is a class of linkable tetrasaccharide compounds that includes the amino phenyl glycoside of sialyl Lewis X (SLe | 2008-12-04 |
20080300221 | Contact Lens Care Composition - The present invention relates to ophthalmic compositions such as contact lens care solutions, containing miltefosine. The present invention further relates to ophthalmic compositions or contact lens care systems containing miltefosine in combination with additional other active microbiocidal substances or proteases. Furthermore, the invention relates to the use of the compositions for the removal and eradication of protozoan parasites such as Acanthamoeba from contact lenses. | 2008-12-04 |
20080300222 | Phosphoantigen Salts Of Organic Bases And Methods For Their Crystallization - The invention provides novel phosphoantigen salts and novel crystalline phases of phosphoantigens salts, that the latter including non-solvated polymorphs, and solvates useful as pharmaceuticals. The invention also provides pharmaceutical compositions comprising, and processes for making, novel phosphoantigen crystalline phases. Methods of using such compositions for the treatment of disease, immunostimulatory or immune response modifying use are also provided. The invention also provides method for obtaining phosphoantigen crystals as well as highly pure phosphoantigen compositions. | 2008-12-04 |
20080300223 | (20R)-2a-Methyl-19,26,27-Trinor-Vitamin D Analogs - This invention discloses (20R)-2α-methyl-19,26,27-trinor-vitamin D analogs, and specifically (20R)-2α-methyl-19,26,27-trinor-1α,25-dihydroxyvitamin D | 2008-12-04 |
20080300224 | TREATMENT OF CONDITIONS RELATING TO HORMONE DEFICIENCIES BY ADMINISTRATION OF PROGESTINS - The present invention includes methods for preventing endometrial hyperplasia associated with estrogen therapy through the administration of a progestin agent. The methods presented may include starting the administration of a progestin agent at a high dose, and then lowering the dose. | 2008-12-04 |
20080300225 | PESTICIDAL FORMULATION CONTAINING OXYMATRINE OR MATRINE - Compositions and methods are provided for a water-soluble insecticidal or pesticidal comprising at least one alkaloid, particularly at least one tetracyclo-quinolizindine alkaloid derived from sophora roots, particularly matrine and/or oxymatrine. | 2008-12-04 |
20080300226 | Combination of Anticholinergics and Glucocorticoids for the Long-Term Treatment of Asthma and COPD - The present invention describes the combination of topically inhaled medicinal formulations comprising an anticholinergic component and a glucocorticosteroid component and its use in the symptomatic and prophylactic treatment of diseases of the respiratory tract, especially with an obstructive component or underlying inflammation like asthma and chronic obstructive pulmonary disease (COPD). It further comprises the presentation of this combination in a locally applied (inhaled) formulation and application in an inhalation device for instance in the Novolizer®. | 2008-12-04 |
20080300227 | Drugs for treating hypertension combined with hyperuricemia and/or hypercholesterolemia - The invention is directed to a drug for treating hypertension combined with serum hyperuricemia and/or hypercholesterolemia, with the active ingredients being 2-propyl-3-{[21-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-5,6,7, 8-tetrahydrocyclohepta imidazole-4-(3H)-one and a prodrug or salt thereof. Pratosartan can be used in combination with one or more diuretics chosen from sulfonamide-, phenoxyacetic acid- and thiazide-type diuretics, triamterene, amiloride, spironolactone, potassium canrenoate and traxanox sodium. Also, pratosartan can be used in combination with one or more hypolipidemic drugs chosen from statins, fibrates, cholesterol absorption inhibitors, cholesterol sequestrants and cholesterol excretion enhancers. | 2008-12-04 |
20080300228 | Crystalline Rostafuroxin - New crystalline forms of 17β-(3-Furyl)-5-βandrostane-3β,14β,17α-triol are described together with pharmaceutical composition containing the same and methods for their preparation. In particular new Forms B, C, D, E and H are here described. | 2008-12-04 |
20080300229 | SPRAYABLE PHARMACEUTICAL COMPOSITIONS COMPRISING A CORTICOID AND AN OILY PHASE - Anhydrous sprayable pharmaceutical/dermatological compositions containing, as active pharmaceutical agent, a corticoid, preferably clobetasol propionate, and an oily phase, are formulated in a physiologically acceptable medium, and are useful for the treatment of a variety of conditions and afflictions, notably psoriasis. | 2008-12-04 |
20080300231 | Antibacterial amide macrocycles VI - The invention relates to antibacterial amide macrocycles and methods for their preparation, their use for the treatment and/or prophylaxis of diseases, as well as their use for the production of medicaments for the treatment and/or prophylaxis of diseases, in particular of bacterial infections. | 2008-12-04 |
20080300232 | N-Piperidine Derivatives as Ccr3 Modulators - Compounds of formula I, processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders and to pharmaceutical compositions containing them. | 2008-12-04 |
20080300233 | Pharmaceutical Composition Comprising Simvastatin and Ezetimibe - The present invention relates to the field of pharmaceutical technology and in particular to novel dosage forms of medicaments containing as active ingredients simvastatin and ezetimibe, or pharmaceutically acceptable salts thereof. The present pharmaceutical compositions are characterized in that the contact of the compositions with oxygen is substantially reduced, such as by coating the composition, providing a medicament useful for the treatment and prevention of atherosclerosis and related conditions, in an environment having an essentially reduced oxygen or humidity, respectively, content. | 2008-12-04 |
20080300234 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH - The present invention relates to a compound of the formula 1 | 2008-12-04 |
20080300235 | FXR Agonists for Reducing LOX-1 Expression - Provided are certain methods of treating at least one disease state characterized by elevated expression of the Lectin-like Oxidized Low-density Lipoprotein Receptor 1 (LOX-1) in a patient with farnesoid X receptor agonists. Also provided are certain methods of reducing expression of LOX-1 in a cell with farnesoid X receptor agonists. | 2008-12-04 |
20080300236 | QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR - This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to quinoline-derived amides that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals. | 2008-12-04 |
20080300237 | Pharmaceutically Active Diazepanes - Leukocyte Function-Associated Antigen One (LFA-1) is a cell adhesion molecule selectively expressed on leukocytes, and plays a major role in the activation and trafficking of T lymphocytes in the tissue at sites of inflammation. In the last decade a large body of preclinical data has accumulated to establish the importance of LFA-1 as a biological target, 10 particularly in chronic, T-cell driven inflammatory conditions. The present invention provides pharmaceutically active 1,4-diazepan-2-ones of formula I useful for the treatment of conditions related to LFA-1 activity. | 2008-12-04 |
20080300238 | PHARMACEUTICAL COMPOSITION COMPRISING A RENIN INHIBITOR, A CALCIUM CHANNEL BLOCKER AND A DIURETIC - The invention relates to a pharmaceutical composition comprising (i) a renin inhibitor, (ii) a calcium channel blocker (CCB), and a diuretic and to a method of using such composition for the treatment of cardiovascular disease. | 2008-12-04 |
20080300239 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS - Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives. | 2008-12-04 |
20080300240 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS - Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. The compounds have the general structure: | 2008-12-04 |
20080300241 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods - Non-steroidal tricyclic quinolinone and tricyclic quinoline compounds and compositions that are agonists, partial agonists and/or antagonists for androgen receptors (AR), their preparation and their uses are described. | 2008-12-04 |
20080300242 | Imidazopyridine Kinase Inhibitors - The present invention provides imidazopyridine compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents. | 2008-12-04 |
20080300243 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same - Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others. | 2008-12-04 |
20080300244 | NOVEL COMPOUNDS - The present invention provides compounds of formula | 2008-12-04 |
20080300245 | Pyrazolo[1,5-A]Pyridine-3-Carboxylic Acids as Ephb and Vegfr2 Kinase Inhibitors - The invention relates to novel pyrazolo[1,5a]pyridine-3-carboxylic acid compounds of the formula | 2008-12-04 |
20080300246 | Compounds and Compositions as Protein Kinase Inhibitors - The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, BMX, BTK, CHK2, b-RAF, c-RAF, CSK, c-SRC, Fes, FGFR3, Flt3, IKKα, IKKβ, JNK2α 2, Lck, Met, MKK4, MKK6, MST2, NEK2, p70S6K, PDGFRβ, PKA, PKBα, PKD2, Rsk1, SAPK2α, SAPK2β, SAPK3, SGK, Tie2 and TrkB kinases. | 2008-12-04 |
20080300247 | Benzimidazole Thiophene Compounds - The present invention provides benzimidazole thiophene compounds pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents. | 2008-12-04 |
20080300248 | Quinazoline Derivatives, Preparation Methods and Uses Thereof - The present invention has disclosed a compound of formula I and a pharmaceutically acceptable salt or a solvate thereof, wherein the substituents are as defined in the description. The invention has also disclosed a method for preparing the compound of formula I, the pharmaceutical compositions comprising the same and their uses in the preparation of an anti-tumor medicament. | 2008-12-04 |
20080300249 | Isothiazole Derivatives Useful as Anticancer Agents - The present invention relates to compounds of the formula 1 | 2008-12-04 |
20080300250 | ACETYLENYL-PYRAZOLO-PYRIMIDINE DERIVATIVES - The present invention relates to compounds of formula (I): | 2008-12-04 |
20080300251 | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors - The present invention relates to novel 3-azabicyclo[3.1.0]hexane derivatives as dipeptidyl peptidase-IV inhibitors and the processes for the synthesis of the said compounds. This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating diabetes, especially type 2 diabetes, as well as prediabetes, diabetic dyslipidemia, metabolic acidosis, ketosis, satiety disorders, and obesity. These inhibitors can also be used to treat conditions manifested by a variety of metabolic, neurological, anti-inflammatory, and autoimmune disorders like inflammatory disease, multiple sclerosis, rheumatoid arthritis; viral, cancer and gastrointestinal disorders. The compounds of this invention can also be used for treatment of infertility arising due to polycystic ovary syndrome. | 2008-12-04 |
20080300252 | EMBEDDING ANTIBIOTIC COMPOUNDS IN SOLID POLYMERS - The present invention is directed to providing antimicrobial compositions consisting of a polymeric material and, embedded therein, an antimicrobial compound. The antimicrobial compound contains at least one quaternary ammonium group, at least one hydrocarbon chain comprising a minimum of 10 carbon atoms and a maximum of 24 carbon atoms, and one or more anions to balance the charge of the quaternary ammonium groups. The invention is also directed to a method of making antimicrobial compositions containing an antimicrobial compound embedded in a polymeric material. | 2008-12-04 |
20080300253 | TREATMENT OF INFLAMMATORY DISORDERS WITH PRAZIQUANTEL - Methods of treating and/or preventing disorders mediated by one or more of TNF-α, NF-κB, IKK-α, IKK-β, ATF-2 and p38 kinase by administration of praziquantel, or a pharmaceutically acceptable salt, prodrug, ester or amide thereof. These disorders include inflammatory disorders such as autoimmune diseases. | 2008-12-04 |
20080300254 | Tylophorine Analogs as Antitumor Agents - Compounds of Formula I are described: preferably subject to the proviso that either (a) R | 2008-12-04 |
20080300255 | Substituted pyrazoles - Substituted pyrazoles, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S. | 2008-12-04 |
20080300256 | Substituted 5,6,7,8-Tetrahydroimidazo[1,2-a]pyridin-2-ylamine Compounds and Their Use for Producing Drugs - Substituted 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-2-ylamine compounds corresponding to formula I, methods for the preparation thereof, pharmaceutical compositions containing said compounds, the use of said compounds for preparing pharmaceutical compositions and related treatment methods. | 2008-12-04 |
20080300257 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES - Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 3-imidazoyl-pyrazolo[3,4-b]pyridine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists. | 2008-12-04 |
20080300258 | ANHYDROUS CIPROFLOXACIN HYDROCHLORIDE - The present invention provides a new anhydrous crystalline form of ciprofloxacin hydrochloride that is substantially free from solvent molecules, and processes of preparation thereof. | 2008-12-04 |
20080300259 | Multimediator 5-Ht6 Receptor Antagonists, and Uses Related Thereto - The invention provides a class of 5HT6—D3/DAT compounds, packaged pharmaceuticals comprising such compounds, and their uses in treating, or manufacturing medicaments for treating disease conditions, including a movement disorder, anxiety, depression or psychotic disorder (e.g. Bipolar Disorder, Bipolar Depression or Unipolar Depression, etc.). Related business methods such as marketing the compounds to healthcare providers are also provided. | 2008-12-04 |
20080300260 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) - The present invention relates to heterocyclic compounds which are positive modulators of metabotropic glutamate receptor. The present invention also relates to the use of these compounds for preparing a pharmaceutical composition and to a method of treating a medical disorder, selected from neurological and psychiatric disorders associated with glutamate dysfunction. | 2008-12-04 |
20080300261 | Arylacetic Acids and Related Compounds for Treatment of Alzheimer's Disease - Compounds of formula I | 2008-12-04 |
20080300262 | Combination Therapy for Relief of Pain - The present invention relates to analgesic compositions comprising a non-peptidyl N-type calcium channel blocker, and at least one other analgesic compound, and to methods of using N-type calcium channel blockers in combination with at least one other pain-relieving compound that alleviates pain through a mechanism other than N-type calcium channel blockage, or with a non-pharmacological therapeutic protocol. | 2008-12-04 |
20080300263 | Pyrazolo [1,5-a] pyrimidine compounds and pharmaceutical compositions containing them - The present invention relates to certain pyrazolo[1,5a]pyrimidine compounds, to processes for their preparation, compositions comprising them and methods of using them. The compounds are useful in the treatment of cancer. Novel screening methods are also provided. | 2008-12-04 |
20080300264 | SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS - The present invention is directed to substituted thiatriazaacenaphthylene-6-carbonitrile compounds of formula (I): | 2008-12-04 |
20080300265 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION - Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to, Arenaviridae (Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, Pichinde, and LCMV), Filoviridae (Ebola and Marburg viruses), Flaviviridae (yellow fever, Omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever and Crimean-Congo hemorrhagic fever). | 2008-12-04 |
20080300266 | 1-(Hetero)Aryl-3-Amino-Pyrrolidine Derivatives for Use as Mglur3 Antagonists - The present invention relates to compounds of the Formula (I) which are useful for treating conditions associated with mGluR3 receptors, such as depression, schizophrenia and migraine, pharmaceutical compositions thereof, and methods of using the same. | 2008-12-04 |
20080300267 | Compounds and Compositions as Protein Kinase Inhibitors - The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the CDKs, Aurora, Jak2, Rock, CAMKII, FLT3, Tie2, TrkB, FGFR3 and KDR kinases. | 2008-12-04 |
20080300268 | HETEROCYCLIC COMPOUNDS AND USES THEREOF - The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | 2008-12-04 |
20080300269 | THERAPEUTIC COMPOUNDS - Disclosed herein are compounds of the formula | 2008-12-04 |
20080300270 | 4-Phenyl-5-Oxo-1,4,5,6,7,8,- Hexahydroquinoline Derivatives as Medicaments for the Treatment of Infertility - The invention relates to a 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivative according to Formula (I), wherein the substituents are defined as in the description, or a pharmaceutically salt thereof. The compounds of this invention are potent FSH receptor activators and may be used for treating fertility disorders in e.g. controlled ovarian hyperstimulation and IVF procedures. | 2008-12-04 |
20080300271 | Novel compounds and a novel process for their preparation - The present invention is directed to a procedure for making an enantidimerically enriched compound containing a hydronaphthalene ring structure. The process involves reacting oxabenzonorbornadienes with nuclophiles using rhodium as a catalyst and in the presence of a phosphine ligand. The compounds synthesized may be used in pharmaceutical preparations for the treatment of a variety of diseases and conditions. | 2008-12-04 |
20080300272 | Alcohol free formulation of argatroban - An aqueous formulation of argatroban and of related compounds is disclosed along with a reconstitutable formulation, each of which is substantially, if not totally alcohol free. The formulations are also substantially free, if not totally free, of mono-, di-, and oligo-saccharides. An especially preferred embodiment is a ready-to-administer 1 mg/ml injectable dosage form having argatroban, lactobionic acid, and methionine. | 2008-12-04 |
20080300273 | Method of Treating Abnormal Cell Growth - The present invention relates to the use of (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine, a novel c-Met/HGFR inhibitor, for treating abnormal cell growth in mammals. In particular, the invention provides methods of treating mammals suffering from cancer. | 2008-12-04 |
20080300274 | Novel Pyrrolidino-1,4-Naphthoquinone Deriviatives and their Use for Treating Malignancies and Cardiovascular Diseases - The invention provides pyrrolidino-substituted 1,4-naphthoquinone derivatives that modulate the activity of protein kinases, and it relates to the use of the derivatives in pharmaceutical compositions for treating cardiovascular disorders and malignancies. The invention particularly provides medicaments for treating disorders associated with MAPKs signaling, ERKs signaling, p38 signaling, and JNKs signaling. | 2008-12-04 |
20080300275 | Novel Benzothiazolone Derivatives - The present invention provides compounds of formula (I) wherein e, R | 2008-12-04 |
20080300276 | Heterocyclic Carboxylic Acide Amide Derivatives - The invention relates to new heterocyclic carboxylic acid amide derivatives of formula (I)—wherein the meaning of X is hydrogen or halogen atom, hydroxy, cyano, C | 2008-12-04 |
20080300277 | PROCESS TO IMPROVE STABILITY OF A PHARMACEUTICAL COMPOSITION - The present invention describes in particular a method for stabilizing a pharmaceutical composition by contacting said composition with a polymeric material comprising in particular an ethylene oxide sterilization step. | 2008-12-04 |
20080300278 | Prodrugs of Pyrazoline Compounds, Their Preparation and Use as Medicaments - The present invention relates to prodrugs of pyrazoline compounds of formula I, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals. | 2008-12-04 |
20080300279 | PIPERIDINE-AMIDE DERIVATIVES - The invention is concerned with novel piperidine-amide derivatives of formula (I) | 2008-12-04 |
20080300280 | Cyanobenzene Compounds for Combating Animal Pests - The present invention relates to a method of combating animal pests which comprises contacting the animal pests, their habit, breeding ground, food supply, plant, seed, soil, area, material or environment in which the animal pests are growing or may grow, or the materials, plants, seeds, soils, surfaces or spaces to be protected from animal attack or infestation with a pesticidally effective amount of at least one cyanobenzene compound of the formula (I) and/or at least one agriculturally acceptable salt thereof: where m is 0, 1 or 2; is a radical of the formulae N═CR | 2008-12-04 |
20080300281 | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas - This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases other than cancer and proteolytic enzyme mediated diseases other than cancer, and pharmaceutical compositions for use in such therapy. | 2008-12-04 |
20080300282 | Novel process to prepare pioglitazone via several novel intermediates - A novel process for preparing thiazolidinediones, preferably Pioglitazone, as described. Also described are novel intermediates involved in its synthesis and process for their preparation and use in medicine. | 2008-12-04 |
20080300283 | Microbicidal preparations based on 1, 2-benzisothiazonlin-3-one with a content of aromatic alcohol - The invention relates to microbicidal preparations which comprise a) at least one of 1,2-benzisothiazolin-3-one and its derivatives, b) at least one of 2-mercaptopyridine N-oxide, its salts and derivatives, c) at least one aromatic alcohol and d) at least one alkalinizing agent, or which are prepared by mixing components a) to d), where the preparations have a pH of at least 11. The preparations are characterized by the fact that they are clear and storage-stable, and they are suitable for use as preservatives. | 2008-12-04 |
20080300284 | NICOTINIC ACID COMPOSITIONS FOR TREATING HYPERLIPIDEMIA AND RELATED METHODS THEREFOR - An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyper lipidemic having a substantially periodic physiological loss of consciousness, includes the steps of forming a composition having an effective antihyperlipidemic amount of nicotinic acid and a time release sustaining amount of a swelling agent. The method also includes the step of orally administering the composition to the hyperlipidemic once per day “nocturnally,” that is in the evening or at night. | 2008-12-04 |
20080300285 | Chemical Compounds - The use of a compound of formula (I) wherein X is (i), (ii) or (iii), formula (i), formula (ii), formula (iii) Y is O, S(O) | 2008-12-04 |
20080300286 | Tyrosine Derivatives Substituted By N-Arylacryloyl as Agonists of Hppar Alpha and/or Hppar Gamma - The present invention relates to a compound of formula I, racemates, optically active isomers, or pharmaceutically acceptable salts or solvates thereof, and a pharmaceutical composition comprising the compound, the various radicals in the formula I are the same as defined in the claims. The present invention also relates to a process for preparing the compound of formula I and use of said compound in the preparation of a medicament for the treatment of hyperglycemia, dyslipidemia, type II diabetes mellitus including associated diabetic dyslipidemia | 2008-12-04 |
20080300287 | Peptidic Compounds - The present invention provides a compound of formula (I), (II), (III) and (IV) as defined herein and pharmaceutically acceptable derivatives thereof. The present invention further provides use of the compounds of the present invention in the treatment of bacterial infection and in the treatment of HIV infection. Also provided are pharmaceutical compositions comprising the compounds of the present invention. | 2008-12-04 |
20080300288 | Alkenyldiarylmethanes, Fused Analogs And Syntheses Thereof - Non-nucleoside inhibitors of HIV-1 reverse transcriptase are described. Such inhibitors may be used as part of a combination therapy to treat HIV infection. Compounds described herein exhibit antiviral potency. In addition, compounds described herein exhibit metabolic stability. Also described herein are processes for preparing Non-nucleoside inhibitors of HIV-1 reverse transcriptase. | 2008-12-04 |
20080300289 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses - The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like. | 2008-12-04 |
20080300290 | Novel Beta-Agonists, Process for Their Preparation and Their Use as Medicaments - Compounds of general formula (I) | 2008-12-04 |
20080300291 | POTENT INDOLE-3-CARBINOL-DERIVED ANTITUMOR AGENTS - Compounds and methods for treating cancer and inducing apoptosis in unwanted rapidly proliferating cells. The compounds are shown in formula I: | 2008-12-04 |
20080300292 | Nitrosated and Nitrosylated Compounds, Compositions and Methods for the Treatment of Ophthalmic Disorders - The invention describes novel nitrosated and/or nitrosylated compounds or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at least one compound of the invention, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor compound and/or at least one therapeutic agent. The invention also provides methods for treating ophthalmic disorders. The nitrosated and/or nitrosylated compounds are preferably nitrosated and/or nitrosylated (3-adrenergic antagonists and nitrosated and/or nitrosylated angiotensin-converting enzyme (ACE) inhibitors. | 2008-12-04 |
20080300293 | COMBINATION OF AN DPP-IV INHIBITOR AND A PPAR-ALPHA COMPOUND - The invention relates to a combination which comprises a DPP-IV inhibitor and at least one further PPARα compound, preferably selected from the group consisting of fenofibrate, micronized fenofibrate, bezafibrate, gemfibrazil and ciprofibrate for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of conditions mediated by DPP-IV and PPARα, in particular diabetes, more especially type 2 diabetes mellitus, conditions of IGT, conditions of impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis, obesity, dyslipidemia and osteoporosis. | 2008-12-04 |
20080300294 | Novel Thiophene Derivatives - The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents. | 2008-12-04 |
20080300295 | Inhibitors of Ccr9 Activity - Compounds of formula I, wherein one of R | 2008-12-04 |
20080300296 | Coating agent for drug releasing stent, preparation method thereof and drug releasing stent coated therewith - Disclosed are a coating agent for drug releasing stents, a method for preparing the same and a drug releasing stent coated therewith. The coating agent comprises a biologically active material and a coating material selected from among pullulan acetate, represented by the following Chemical Formula 1, and a polyurethane-surfactant mixture. | 2008-12-04 |
20080300297 | Taxane derivative containing pharmaceutical composition with improved therapeutic efficacy - The invention relates to a pharmaceutical combination comprising a mixture of (a) at least one taxane derivative and (b) at least one ω-3 poly-unsaturated acid or a derivative thereof wherein the molar ratio of (b) to (a) is not higher than 2. The invention further relates to a liquid pharmaceutical composition comprising (a) an effective amount of at least one taxane derivative, (b) an effective amount of at least one ω-3 poly-unsaturated fatty acid or a derivative thereof and (c) at least one pharmaceutically acceptable carrier and a process for the preparation of the same. The composition can be used for the therapy of cancers which are sensitive to taxane derivatives. The invention also relates to a kit comprising the individual components of the above mentioned composition placed in separate containers. | 2008-12-04 |
20080300298 | Honokiol Derivates For the Treatment of Proliferative Disorders - The present invention provides novel honokiol derivatives, as well as pharmaceutical compositions containing the honokiol derivatives. These compounds and pharmaceutical compositions can be used in the prevention and/or treatment of cancer. In particular, honokiol derivatives, pharmaceutical compositions comprising the derivatives, and methods for their use in the treatment of myeloma are provided. | 2008-12-04 |
20080300299 | Application of Eriocalyxin B in the Manufacture of Medicaments For Treating Leukemia - The use of eriocalyxin B in the manufacture of medicaments for treating leukemia, wherein the leukemia include leukemia containing AML1-ETO fusion protein, acute promyelocytic leukemia, acute myelocytic leukemia and lymphocytic leukemia. Eriocalyxin B increases the level of peroxidate and influences the phosphorylation and degradation of IκBα to prevent NF-κB from getting into the nucleus in order to inhibition NF-κB pathway. Eriocalyxin B can decrease the phosphorylation of ERI1/2 and inhibit MAPK pathway. Eriocalyxin B can extend the life span of mice and decrease tumor volume in mice model of C57 leukemia and tumor transplantation. | 2008-12-04 |
20080300300 | Use of alpha-mangostin as a mosquito larvicide - Methods of killing mosquito larvae and controlling an adult mosquito population by using α-mangostin, 3,6,8-yrihydroxy-2-methoxy-1,7-bis(3-methylbut-2-enyl)xanthen-9-one, or a salt, solute, hydrate or solvate thereof. Mosquito larvae are killed by contacting a lethal dose of α-mangostin with mosquito larvae. Adult mosquito populations are controlled by treating a mosquito larvae population with a lethal dose of α-mangostin. | 2008-12-04 |
20080300301 | Composition for Promoting Production of Hyaluronic Acid Containing Kaempferol and Quercetin - Disclosed is a composition for promoting a production of hyaluronic acid containing at least one of kaempferol and quercetin. Kaempferol and quercetin of the invention increase an expression of a hyaluronic acid synthase (HAS) gene existing in a skin cell line of human epidermis, thereby promoting a production of hyaluronic acid in the human cell. Accordingly, the composition containing at least one of kaempferol and quercetin according to the invention can be usefully used as a cosmetic composition for increasing skin elasticity and preventing skin dryness or aging, or a pharmaceutical composition for treating or preventing a degenerative arthritis. | 2008-12-04 |
20080300302 | Stabilized 3-Hydroxyflavan Compositions and Methods Therefor - Compositions and methods are directed to covalent adducts between reducing agents and optionally substituted 3-hydroxyflavans, wherein the reducing agent is covalently bound to the B-ring of the 3-hydroxyflavan. Such adducts exhibit markedly increased stability towards oxidation as compared to the unmodified 3-hydroxyflavan. Particularly preferred 3-hydroxyflavans include green tea catechins, and especially EGCG, while especially preferred reducing agents include NAC and glutathione. | 2008-12-04 |
20080300303 | Substances and Pharmaceutical Compositions for the Inhibition of Glyoxalases and Their Use As Anti-Fungal Agents - The present invention pertains to substances of the formula (I) wherein X is O or S; and R1-R4 are defined in the claims as inhibitors of glyoxalase I and/or II, pharmaceutical compositions comprising one or more compounds according to formula (I) and the use of one or more compounds according to formula (I) for the treatment of diseases associated with increased glycolytic metabolism. In one embodiment, the disease is a fungal infection. | 2008-12-04 |
20080300304 | Ginger Fraction For Inhibiting Human Cyp Enzymes - The present invention relates to a process for preparing a ginger fraction, the fraction prepared by this process and the use thereof on its own or combined with drugs for inhibiting human cytochrome P450 (CYP) enzymes (particularly cytochrome P450 3A4, CYP3A4) for positively influencing the oral bioavailability and pharmacokinetics of active substances. | 2008-12-04 |
20080300305 | METHOD OF PURIFYING PRAVASTATIN - The present invention provides pure pravastatin compositions and pure compactin compositions, and methods for the preparation thereof. | 2008-12-04 |
20080300306 | Novel Compounds - Compounds of formula (I); | 2008-12-04 |
20080300307 | STABLE GABAPENTIN COMPOSITIONS - Stable compositions containing gabapentin compositions, methods of preparing such compositions, and methods of using such compositions. | 2008-12-04 |
20080300308 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses - The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like. | 2008-12-04 |
20080300309 | Creatine Hydroxycitric Acids Salts and Methods for their Production and use in Individuals - Methods of production for Tricreatine Hydroxycitrate are disclosed. Tricreatine hydroxycitrate can be used as supplemental dietary ingredient for the purposes of reducing adiposity, suppression of appetite, improvement of muscle and exercise performance and recovery. The salts are useful in the dietetic, food supplement and food industries. | 2008-12-04 |
20080300310 | Methods of administering diclofenac compositions for treating photodamaged skin, rosacea and/or acne - A method of treating at least one dermatological disorder selected from the group consisting of photodamage-induced wrinkles, rosacea, and acne, includes: (a) providing a composition containing 1-3 wt. % diclofenac or a salt thereof, 0.5-1.5 wt. % benzyl alcohol, 10-30 wt. % PEG monomethyl ether, 0.1-3.0 wt. % sodium hyaluronate; and 70-80 wt. % water; and (b) applying the composition to skin of a person in need of the treating in an amount effective to treat the at least one dermatological disorder. | 2008-12-04 |
20080300311 | DICLOFENAC GEL - The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis. | 2008-12-04 |
20080300312 | Treatment of cancer with specific RXR agonists - A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose. | 2008-12-04 |
20080300313 | Solvent Mixture for Preparing Water-Dilutable Liquid Concentrate Formulation of Organic Pesticide Compounds - The present invention relates to a solvent mixture SM for preparing a water-dilutable liquid concentrate formulation of sparingly soluble organic pesticide compounds C having a water solubilty of not more than 5 g/l at 25° C./1013 mbar. The present invention also relates to water-dilutable liquid concentrate formulation, which comprises said solvent mixture SM and at least one non-ionic surfactant. | 2008-12-04 |
20080300314 | Cooling Compounds - Compounds of the formula I give a cooling sensation to the mouth and skin: | 2008-12-04 |
20080300315 | Stabilized Compositions Comprising a Therapeutically Active Agent, and an Oxidizing Preservative - Citric acid and conjugate bases thereof are useful for stabilizing stabilized chlorine dioxide in the presence of therapeutically active agents and excipients in a composition. Ophthalmic compositions and methods related thereto are also disclosed herein. | 2008-12-04 |